Gilead Sciences 4Q Revenues: $899.2 million (+48%) 4Q Loss: $1.7 billion (earnings were $281.6 million 4Q2005) FY Revenues: $3 billion (+49%) FY Loss: $1.2 billion (earnings were $813 million FY2005) Comments: Record sales in the quarter and FY were primarily driven by the company’s HIV product franchise of Truvada, Viread and Emtriva, including the strong uptake of Atripla following its July 2006 launch in the U.S. HIV product sales were $642.4 million in the quarter,...